Structural determinants of membrane fusion by HSV-1 gB
Project Number1R21AI065886-01
Contact PI/Project LeaderHELDWEIN, EKATERINA
Awardee OrganizationBOSTON CHILDREN'S HOSPITAL
Description
Abstract Text
DESCRIPTION (provided by applicant): Herpes simplex viruses infect their hosts for life, causing cold sores (HSV-1), eye and genital infections (HSV-1 and -2), and encephalitis. Furthermore, they can wreak havoc in immuno-compromised individuals or in newborns. Host cell entry by HSV-1 requires four viral envelope glycoproteins: gB, gD, and gH/gL complex. Binding of gD to a cell-surface receptor, which triggers fusion events, has been studied crystallographically. By contrast, no structural information is available on the other three proteins, and little is known about how they participate in cell entry. Knowing the structures of all the components of the membrane fusion machinery is a necessary step in unveiling the mechanism of HSV cell fusion. Our long-term goal is to elucidate the mechanism of Herpes virus entry into host cells at the atomic level and to use this knowledge to design effective inhibitors of viral entry into cells for preventative and therapeutic purposes. In preliminary studies, we have crystallized the ectodomain of gB and are currently determining its structure. In this application we propose biochemical and structural studies of additional domains and larger forms of gB, in order to build a more complete picture of its activities and interactions The three specific aims are 1) to determine the structure of the cytoplasmic domain of gB; 2) to produce pure, soluble forms of gB encompassing multiple domains for structural studies; and 3) to study the mechanism of the antiviral effect of a G-quartet oligonucleotide crystallographically. This structural information will provide the framework for elucidating the function of gB in cell entry. For example, known functional mutations will be mapped onto the structure. Moreover, strategies developed for producing soluble multidomain forms of gB for structural studies will allow us to approach gH/gL and, eventually, to assemble multi-protein complexes.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
076593722
UEI
Z1L9F1MM1RY3
Project Start Date
01-June-2005
Project End Date
31-May-2007
Budget Start Date
01-June-2005
Budget End Date
31-May-2006
Project Funding Information for 2005
Total Funding
$168,666
Direct Costs
$100,000
Indirect Costs
$68,666
Year
Funding IC
FY Total Cost by IC
2005
National Institute of Allergy and Infectious Diseases
$168,666
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI065886-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI065886-01
Patents
No Patents information available for 1R21AI065886-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI065886-01
Clinical Studies
No Clinical Studies information available for 1R21AI065886-01
News and More
Related News Releases
No news release information available for 1R21AI065886-01
History
No Historical information available for 1R21AI065886-01
Similar Projects
No Similar Projects information available for 1R21AI065886-01